CD20 Knockout Raji/Luciferase Cell Line

Description

CD20 Knockout Raji/Luciferase Cell Line is a genetically engineered B-lymphocyte model derived from Raji cells (a human Burkitt’s lymphoma line) featuring dual modifications: stable integration of luciferase (Luc) reporter gene and complete knockout of CD20 (MS4A1) expression. This cell line maintains characteristic Raji cell morphology and growth properties while providing sensitive bioluminescence detection capability for in vivo tracking and quantitative tumor burden assessment. The CD20 knockout eliminates target expression for anti-CD20 therapies (e.g., rituximab), making this line particularly valuable for immunotherapy resistance studies, engineered CAR-T cell validation, and investigation of alternative B-cell targeting strategies. Cells exhibit stable luciferase expression across passages (<P20) with consistent growth kinetics, enabling longitudinal studies in xenograft models. The cell line is rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, Fungi, Yeast and Bacteria.

Application

• FOR RESEARCH USE ONLY
  

• The CD20 Knockout Raji/Luciferase Cell Line is a genetically engineered B-cell lymphoma model combining CD20 knockout with stable luciferase reporter expression. This dual-modified cell line enables sensitive bioluminescence imaging for in vivo tumor tracking while serving as a powerful tool for studying CD20-independent mechanisms and resistance to anti-CD20 therapies. Ideal for xenograft studies, drug screening, and immunotherapy development, it maintains consistent reporter activity and knockout phenotype when cultured in RPMI-1640 medium with 10% FBS and appropriate selection antibiotics.